Uncoupling of myofilament Ca²⁺-sensitivity from troponin I phosphorylation by mutations can be reversed by Epigallocatechin-3-Gallate

Maria Papadaki, **Petr G. Vikhorev**, **Steven B. Marston**, and **Andrew E. Messer**
National Heart and Lung Institute, Imperial College London, London, W12 0NN, UK

Abstract

Aims—Heart muscle contraction is regulated *via* the β-adrenergic response that leads to phosphorylation of Troponin I (TnI) at Ser22/23, which changes the Ca^{2+}-sensitivity of the cardiac myofilament. Mutations in thin filament proteins that cause Dilated Cardiomyopathy (DCM) and some mutations that cause Hypertrophic Cardiomyopathy (HCM) abolish the relationship between TnI phosphorylation and Ca^{2+}-sensitivity (uncoupling). Small molecule Ca^{2+}-sensitisers and Ca^{2+}-desensitisers that act upon troponin alter the Ca^{2+}-sensitivity of the thin filament but their relationship with TnI phosphorylation has never been studied before.

Methods and Results—Quantitative *in vitro* motility assay showed that 30 μM EMD57033 and 100 μM Bepridil increase Ca^{2+}-sensitivity of phosphorylated cardiac thin filaments by 3.1 and 2.8-fold respectively. Additionally they uncoupled Ca^{2+}-sensitivity from TnI phosphorylation, mimicking the effect of HCM mutations. EGCG decreased Ca^{2+}-sensitivity of phosphorylated and unphosphorylated wild-type thin filaments equally (by 2.15±0.45 and 2.80±0.48-fold respectively), retaining the coupling. Moreover, EGCG also reduced Ca^{2+}-sensitivity of phosphorylated but not unphosphorylated thin filaments containing DCM and HCM-causing mutations, thus the dependence of Ca^{2+}-sensitivity upon TnI phosphorylation of uncoupled mutant thin filaments was restored in every case. In single mouse heart myofibrils, EGCG reduced Ca^{2+}-sensitivity of force and k_{ACT} and also preserved coupling. Myofibrils from the *ACTC* E361G (DCM) mouse were uncoupled; EGCG reduced Ca^{2+}-sensitivity more for phosphorylated than unphosphorylated myofibrils, thus restoring coupling.

Conclusion—We conclude that it is possible to both mimic and reverse the pathological defects in troponin caused by cardiomyopathy mutations pharmacologically. Re-coupling by EGCG may be of potential therapeutic significance for treating cardiomyopathies.

Introduction

Hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM) are common inherited diseases. HCM is detected in 1 in 500 of the adult population and the causative

Correspondence should be addressed to: **Andrew Messer PhD**, Myocardial Function, Imperial Centre for Translational and Experimental Medicine, Hammersmith Campus, Du Cane Road, London, W12 0NN, UK, Tel: +44 (0)207 594 2732, Mobile: +44 (0)7722 966655, a.messer@imperial.ac.uk.

Conflict Of Interest Statement
The authors declare no conflict of interest.

mutations are overwhelmingly in the proteins of the cardiac muscle contractile apparatus 1, 2. At least 30% of cases of idiopathic DCM are of genetic origin, and DCM with no additional complications such as conduction disease is usually caused by mutations in the contractile apparatus 3, 4. In many cases, the cardiomyopathies result from missense mutations in one of the proteins of the muscle thin filament (actin, tropomyosin, troponin I, C or T). Investigations of the mechanisms that cause HCM and DCM have generally found that mutations in the muscle thin filament cause abnormalities in the Ca^{2+}-regulatory system of the muscle 5–7.

HCM is closely associated with enhanced myofilament Ca^{2+}-sensitivity although the process by which chronically high Ca^{2+}-sensitivity leads to the symptoms of HCM: hypertrophy, fibrosis and arrhythmias, is uncertain. In DCM, the situation is more complex. It has been suggested that DCM-causing mutations are associated with a reduced Ca^{2+}-sensitivity 8 but comprehensive surveys now show that DCM-causing mutations in thin filament proteins can increase or decrease Ca^{2+}-sensitivity 5, 9. However, the DCM phenotype is always linked to the absence of modulation of Ca^{2+}-sensitivity by troponin I (TnI) phosphorylation (uncoupling) and this has been proposed to be causative of the DCM phenotype 9, 10. In addition, the coupling between TnI phosphorylation and change of Ca^{2+}-sensitivity seems to be lost due to HCM mutations in thin filament proteins when studied by *in vitro* motility assay (IVMA) techniques and in myofibrilar assays 11–15, but in permeabilized muscle this phenomenon is not observed 16. Thus, in HCM the relationship between TnI phosphorylation and Ca^{2+}-sensitivity is not clear.

Uncoupling appears to be closely associated with mutations in thin filament proteins that cause cardiomyopathies. The decrease in Ca^{2+}-sensitivity upon phosphorylation of TnI and the corresponding increase in the rate of Ca^{2+}-dissociation from troponin C (TnC), is a key component of the lusitropic response to β1-adrenergic stimulation in the heart. The uncoupling reported in DCM and HCM, is likely to impact on cardiac reserve pathologically, and indeed, most studies of mouse models with cardiomyopathy mutations in thin filament proteins report a blunted response to adrenergic stimulation *in vivo* (reviewed in 17).

A number of small molecules have been found that alter myofilament Ca^{2+}-sensitivity by binding to troponin and act as either Ca^{2+}-sensitisers or Ca^{2+}-desensitisers. The effect of these reagents on Ca^{2+}-sensitivity is well documented, but the effect of small molecules on the coupling between Ca^{2+}-sensitivity and TnI phosphorylation has not previously been considered.

EMD57033 and Bepridil are well established Ca^{2+}-sensitisers acting directly upon TnC 18–20. Epigallocatechin-3-Gallate (EGCG), the principal polyphenol isolated from green tea, is reported to be a Ca^{2+}-desensitiser that also acts *via* a binding site on TnC 21–23. Structural studies indicate that the regulatory Ca^{2+} binding site (site II in the N-terminal lobe of TnC) is closely coupled both to the binding of the TnI switch peptide (147-163), critical for neutralising the inhibitory action of TnI, and the cardiac specific N-terminal peptide of TnI (1-30) that contains the phosphorylatable serines 22 and 23 24–28. We have proposed that DCM-causing mutations in thin filament proteins uncouple phosphorylation from the change

in Ca^{2+}-sensitivity by disrupting this coupled allosteric system [9, 17]. It is likely that Ca^{2+}-sensitisers and desensitisers binding to TnC would also have an effect on the coupling between Ca^{2+}-sensitivity and TnI phosphorylation by modulating the coupled system.

We have therefore investigated how EMD57033, Bepridil and EGCG affect Ca^{2+}-regulation and its modulation by phosphorylation in native human heart thin filaments and how these reagents interact with mutations in thin filament proteins associated with HCM or DCM. Using IVMA and single myofibril contractility we have confirmed the Ca^{2+}-sensitising effects of EMD57033 and Bepridil and demonstrated that they also uncouple Ca^{2+}-sensitivity from the TnI phosphorylation level, thus mimicking the effects of HCM-causing mutations. In contrast, EGCG decreases Ca^{2+}-sensitivity in native thin filaments whilst retaining the modulation of Ca^{2+}-sensitivity by TnI phosphorylation. Moreover, EGCG has the unique ability to restore the coupling to uncoupled HCM and DCM mutant thin filaments and myofibrils, thus antagonising the disease-causing defect. This property of EGCG may be of therapeutic significance for treating some cardiomyopathies.

Methods

Sources of contractile proteins

Donor heart tissue, used as control, and end-stage failing heart tissue from explanted hearts were obtained from the Sydney Tissue Bank Sydney, Australia [1,2]. Ethical approval for collection and use of tissue samples was obtained from the St Vincent's Hospital, Sydney and Brompton, Harefield and NHLI Research Ethics Committees.

Troponin was isolated from 100 mg of human heart muscle using an anti-cardiac troponin I (TnI) monoclonal antibody affinity column as described by Messer [29]. Troponin containing the *TNNC1* G159D mutation was purified from explanted heart samples as previously described [30,9, 31]. Recombinant *TNNT2* K280N and *TNNI3* K36Q was introduced into donor heart troponin by exchange as described [29, 32]. Wild-type α-tropomyosin (Tpm1.1) and the mutants E40K, E54K and E180G were expressed in a baculovirus/*Sf*9 system with a protocol based on that of Akkari *et al.* [9, 33, 34]. Native, E361G and E99K mutant mouse cardiac actins were extracted from transgenic mouse hearts as described by Song *et al.* [35].

Manipulation and measurement of TnI phosphorylation level

Troponin isolated from human heart samples has a high level of phosphorylation, which was reduced by treatment with shrimp alkaline phosphatase (Sigma P9088). Recombinant TnI was phosphorylated by treatment with protein kinase A (PKA) catalytic subunit (Sigma, P2645-400) as previously described. [9, 32]. To dephosphorylate mouse heart troponin, mice were treated with Propranolol as described [10]. TnI phosphorylation levels in myofibrils and isolated troponin was measured by Phosphate affinity SDS-PAGE as described [9, 36], results are shown in Supplement C.

Quantitative *in vitro* motility assay

Thin filaments were reconstituted with 10 nM rabbit skeletal or mouse cardiac muscle α-actin (labelled with TRITC phalloidin), tropomyosin (40-60 nM) and troponin (60 nM) to

study Ca^{2+}-regulation of filament motility by the quantitative *in vitro* motility assay 29, 37. Thin filament movement over a bed of immobilised rabbit fast skeletal muscle heavy meromyosin (100 μg/ml) was compared in paired motility chambers in which troponin varied by a single factor (mutation, phosphorylation state or treatment with drug). Filament movement was recorded and analysed as previously described 38, yielding two parameters, the fraction of filaments moving and the speed of moving filaments.

Contraction of isolated myofibrils

Contraction and relaxation of isolated mouse myofibrils was initiated using a fast-solution change system and sensitive force transducer system recently described 10. Further details are in Supplement A.

Results

Relationship between phosphorylation and Ca^{2+}-sensitivity

We measured the Ca^{2+}-dependence of thin filaments containing human heart troponin by the *in vitro* motility assay (IVMA). The assay yields two parameters, fraction of filaments motile and sliding speed of the motile thin filaments. Both parameters are Ca^{2+}-dependent and Ca^{2+}-activation curves were plotted (Figure 1A). 3.9 μM Ca^{2+} increased the fraction of filaments motile from 0.03 to 0.83 and the sliding speed from 1.5 μm/sec to 3.0 μm/sec. The EC_{50} and Hill co-efficient (n_H) determined by fitting the Hill equation to the data were similar for both parameters under all conditions; therefore, in this manuscript we have only shown the fraction motile parameter. Full data for both parameters is shown in Supplement B.

Human heart troponin has a high level of TnI phosphorylation in the 1.4-1.8 mols Pi/mol range 36. This is reduced to less than 0.3 mols Pi/mol by treatment with phosphatase, see Supplement C. The Ca^{2+}-sensitivity of unphosphorylated thin filaments is 1.88±0.10 (p<0.0001, n=16) times greater than the native phosphorylated thin filaments as reported previously 29. n_H was significantly reduced from 2.11±0.18 for phosphorylated to 1.72±0.11 for unphosphorylated thin filaments, p=0.017, n=16. The maximum sliding speed was not significantly affected by phosphorylation level (Table 1, Figure 1A).

We have investigated thin filaments incorporating 6 DCM-causing mutations that have been shown to abolish this relationship (uncouple) in previous studies 9 and 3 HCM mutations that uncouple *in vitro* (Figure 1B 15, 39).

EMD57033 and Bepridil increase Ca^{2+}-sensitivity and uncouple TnI phosphorylation from changes in Ca^{2+}-sensitivity

EMD57033 and Bepridil substantially increased the Ca^{2+}-sensitivity (Figure 2) and slightly increased the maximum sliding speed of native human thin filaments as expected.

The effect of EMD57033 on EC_{50} for Ca^{2+}-activation of motility was biphasic with a maximum at 30 μM and an EC_{50} in the range 15-20 μM (Figure 2C). Interestingly, we observed that 30 μM EMD57033 increased the Ca^{2+}-sensitivity of thin filaments containing phosphorylated troponin more than unphosphorylated TnI (mean ratio EC_{50} P/EC_{50} P +

EMD57033 = 3.07±0.71, p=0.0001, n=4 in phosphorylated compared with a mean ratio of EC_{50} unP/EC_{50} unP + EMD57033 = 1.83±0.36, p=0.07, n=4 in unphosphorylated, see Table 1, Figure 2A, Supplement B).

Consequently, in the presence of EMD57033, Ca^{2+}-sensitivity of thin filaments was the same, independent of the level of phosphorylation (EC_{50} P + EMD57033/EC_{50} unP + EMD57033 = 1.08±0.03, p=0.06, n=4). EMD57033 increased sliding speed slightly at saturating Ca^{2+} concentration in phosphorylated thin filaments and in unphosphorylated thin filaments by 18.4±4.1% (p=0.02, n=4). n_H was slightly decreased in phosphorylated but not unphosphorylated thin filaments. EMD57033 also increased the Ca^{2+}-sensitivity of thin filaments containing the DCM-causing mutations, *TPM1* E40K and E54K. In both these cases, Ca^{2+}-sensitivity was independent of troponin phosphorylation (uncoupled) due to the mutation (Table 1, Figure 2B).

A similar pattern of results was observed with Bepridil. The dose-response curve was cooperative with a calculated EC_{50} of 52 μM (Figure 2F). At 100 μm, which is the saturated concentration, the increase in Ca^{2+}-sensitivity of phosphorylated donor thin filaments (measured by the mean ratio EC_{50} P/EC_{50} P + Bepridil) was 2.8±0.14-fold for fraction motile (p<0.0001, n=6) and 3.09±0.59-fold for sliding speed (p=0.016, n=6), see Supplement B.

Bepridil increased the Ca^{2+}-sensitivity of thin filaments and also uncoupled Ca^{2+}-sensitivity from TnI phosphorylation, as shown by the EC_{50} ratios of phosphorylated to dephosphorylated troponin (EC_{50} P/EC_{50} unP = 1.73±0.03, p<0.0001; EC_{50} P + Bepridil/EC_{50} unP + Bepridil = 1.03±0.01, p=0.04, n=6) (Figure 2D, Supplement B). Bepridil increased sliding speed at saturating Ca^{2+} concentrations significantly in phosphorylated thin filaments (14.8±3.2%, p=0.006, n=6) but did not have a significant effect in unphosphorylated thin filaments (7.2±4.6%, p=0.18, n=6); it had no significant effect on n_H. Bepridil also reversibly increased the Ca^{2+}-sensitivity of both phosphorylated and unphosphorylated thin filaments containing the DCM-causing *TPM1* E54K mutation and these mutant thin filaments remained uncoupled (Table 1, Figure 2E, Supplement E).

EGCG decreases Ca^{2+}-sensitivity whilst retaining coupling

EGCG decreased Ca^{2+}-sensitivity of human cardiac thin filaments measured by IVMA and at saturating concentrations (100 μM) reduced the maximum sliding speed up to 20% but had no significant effect on n_H (Table 1, Figure 3, Supplement B). Titration of EGCG at 0.074 μM Ca^{2+} yielded a cooperative dose-response curve with a calculated EC_{50} of 70±7 μM for phosphorylated and 60±1 for unphosphorylated (Figure 3C). Unlike EMD57033 and Bepridil, 100 μM EGCG had a similar effect on the EC_{50} of thin filaments with phosphorylated and unphosphorylated troponin, (mean ratio EC_{50} + EGCG/EC_{50} control = 2.15±0.45-fold for phosphorylated and 2.80±0.48-fold for unphosphorylated thin filaments, see Supplement B). Therefore, the coupling of TnI phosphorylation level to changes in Ca^{2+}-sensitivity was retained (EC_{50} P/EC_{50} unP = 2.24±0.10, p<0.0001, n=6; EC_{50} P + EGCG/EC_{50} unP + EGCG = 1.73±0.16, p=0.006, n=6) (Table 1, Figure 3A, Supplement B).

EGCG restores coupling to HCM and DCM mutant thin filaments and myofibrils

EGCG also affected Ca^{2+}-sensitivity in thin filaments containing mutations associated with HCM or DCM in a phosphorylation-dependent way. This was tested with five DCM-causing mutations and three HCM-causing mutations. EGCG decreased the Ca^{2+}-sensitivity of phosphorylated mutant thin filaments in a similar way to wild-type troponin (Ratio EC_{50} with/without EGCG was 1.36-2.85). However, with unphosphorylated troponin EGCG tended to have no effect or, in the case of the three tropomyosin mutations, increased Ca^{2+}-sensitivity (Table 2). As a result, the dependence of Ca^{2+}-sensitivity on TnI phosphorylation level was restored. For example, thin filaments containing the DCM-causing *TPM1* mutation E54K were uncoupled with EC_{50} of 0.106±0.013 µM for phosphorylated and 0.114±0.019 µM for unphosphorylated giving a ratio of 0.95±0.03 compared with a ratio of 2.24±0.10 for wild-type thin filaments (Table 1). In the presence of 100 µM EGCG, the EC_{50} were 0.23±0.03 µM for phosphorylated and 0.071±0.005 µM for unphosphorylated giving a ratio of 3.17±0.37 (p=0.004, n=5) (Table 1, Figure 3B). A dose-response assay for recoupling yielded an EC_{50} of 58.8±13.3 µM (Figure 3D). Similarly, EGCG was able to reversibly restore coupling of all the thin filament HCM and DCM-causing mutations in this study (Table 2, Figures 4 and 5, Supplement F).

The effect of EGCG on contraction of myofibrils

We studied the effect of EGCG on mouse myofibril contractility in basally phosphorylated and dephosphorylated states, obtained by treating mice with propranolol prior to sacrifice (Table 3, Figure 6).

We found that 10 µM EGCG decreased Ca^{2+}-sensitivity of isometric force for both phosphorylated and unphosphorylated mouse myofibrils equally (EC_{50} P/EC_{50} P + EGCG = 0.50±0.06, p<0.001, n=9, EC_{50} unP/EC_{50} unP + EGCG = 0.45±0.07, p<0.00, n=5). Consequently, the effect of phosphorylation on Ca^{2+}-sensitivity in wild-type myofibrils was preserved in the presence of EGCG (EC_{50} P + EGCG/EC_{50} unP + EGCG = 1.64±0.24, p<0.001, n=5).

As previously shown 10, in myofibrils from *ACTC* E361G DCM mice, the Ca^{2+}-sensitivity of force is uncoupled (Table 3, Figure 6). EGCG decreased Ca^{2+}-sensitivity in myofibrils from *ACTC* E361G mice; however, this effect was greater in phosphorylated myofibrils than unphosphorylated myofibrils. Thus, EGCG restored the phosphorylation-dependent shift in Ca^{2+}-sensitivity for *ACTC* E361G myofibrils to the same level as in wild-type myofibrils (EC_{50} P + EGCG/EC_{50} unP + EGCG = 1.62±0.20, p<0.01, n=5 compared with 1.82±0.24 for wild-type in the absence of EGCG). n_H values were similar to those found in wild-type myofibrils (Table 3). The duration of the initial, nearly isotonic, phase of relaxation, t_{LIN}, in phosphorylated and unphosphorylated *ACTC* E361G myofibrils was restored to wild-type values (Table 3). EGCG decreased the rate of force development (k_{ACT}) but did not affect maximum force. k_{ACT} was decreased by EGCG in unphosphorylated wild-type myofibrils (decreased by 22.8%, p=0.059, n=15) as well as in phosphorylated and unphosphorylated *ACTC* E361G (decreased by 23%, p<0.05, n=10 and by 21%, p<0.001, respectively, n=11).

Discussion

In previous studies it was found that mutations in proteins of the cardiac muscle thin filament that are associated with inherited cardiomyopathies (HCM and DCM) alter myofibrillar Ca^{2+}-sensitivity. They also cause the modulation of myofilament Ca^{2+}-sensitivity to become independent of the PKA-dependent phosphorylation of TnI. We have named this phenomenon uncoupling. Moreover, this uncoupling effect may be sufficient to generate the disease phenotype of familial DCM 9, 17. We have investigated whether small molecules might be able to mimic or reverse the molecular effects of mutations.

The Ca^{2+}-sensitisers EMD57033 and Bepridil, known to bind to TnC, induce uncoupling in wildtype thin filaments, thus mimicking the effects of HCM mutations. The Ca^{2+}-desensitiser EGCG has an opposite effect. It preserves coupling in wild-type troponin and restores coupling to thin filaments with HCM and DCM-causing mutations in TnI, TnC, TnT, tropomyosin and actin, thus antagonising the effect of the HCM or DCM mutation. These findings suggest the potential of EGCG for treating the symptoms of inherited cardiomyopathies.

Ca^{2+}-sensitisers mimic the effects of HCM-causing mutations in thin filaments

Both EMD57033 and Bepridil increase Ca^{2+}-sensitivity of phosphorylated thin filaments by 2.8 and 2.9-fold, measured by quantitative IVMA, in common with previous measurements 40, 41. However, it has not been shown before that they increase Ca^{2+}-sensitivity of unphosphorylated thin filaments considerably less than phosphorylated thin filaments. As a consequence, Ca^{2+}-sensitivity becomes independent of the TnI phosphorylation level (uncoupled).

The effect of Ca^{2+}-sensitisers is analogous to the effect of HCM-causing mutations *in vitro* (see Table 2) where both an increase in the Ca^{2+}-sensitivity and uncoupling of the Ca^{2+}-sensitivity from the TnI phosphorylation are observed. Uncoupling due to HCM mutations was first reported in 2001 13 and several more thin filament mutations have subsequently been demonstrated by *in vitro* assays 5, 17, as the *TPM1* E180G mutation, shown in Figure 1B, demonstrates.

Mechanistic considerations of Ca^{2+}-sensitisers

Since both EMD57033 and Bepridil appear to modulate Ca^{2+}-sensitivity with a minimal effect on the sliding speed in IVMA or maximum isometric force in muscle fibres 10, 42 it is likely that they are acting on troponin rather than the cross-bridge cycling mechanism in our systems.

The Ca^{2+}-sensitivity of cardiac troponin is modulated by the unique N-terminal peptide of TnI (1-30) that contains the PKA phosphorylation sites, Ser22 and 23. When unphosphorylated the peptide interacts with the N-terminal domain of TnC, close to the regulatory Ca^{2+}-binding site and this interaction is lost or reduced when the two serines are phosphorylated 43, 44. The change in Ca^{2+}-sensitivity with TnI phosphorylation is a 2-3 fold reduction.

Bepridil is suggested to displace TnI 1-30 and/or the linker helix TnI 31-70 20, 45. EMD57033 is believed to bind to the C-terminal domain of TnC and also displaces the TnI 31-70 peptide 18, 19, 46. Thus both these compounds could act allosterically by interfering with the modulation of Ca^{2+}-sensitivity due to Ser22/23 phosphorylation, resulting in uncoupling.

Interestingly, in experiments measuring isometric force in cardiac muscle myofibrils, EMD57033 increased Ca^{2+}-sensitivity but only caused uncoupling at short sarcomere lengths. Thus the uncoupling phenomenon may be graded rather than all-or-none. One possibility is that uncoupling may be related to Ca^{2+}-sensitivity if the Ca^{2+}-sensitiser shifts the conformational equilibrium so far towards the N-terminal bound conformation that it cannot be significantly influenced by phosphorylation of the N-terminal peptide of TnI (see Supplement D). However the Ca^{2+}-sensitising property of these compounds does not necessarily involve the same molecular mechanism as uncoupling.

The actions of small molecules that uncouple highlights the crucial role of the allosteric coupling between the TnI 1-30 peptide and ligand binding sites that could be remotely located. Likewise, it is notable that DCM-causing mutations that uncouple are distributed in all the proteins of the thin filament, also demonstrating long-range allosteric interactions 9, 47. We have proposed that these mutations destabilize the unphosphorylated state of the 1-30 peptide 9.

The Ca^{2+}-desensitiser EGCG restores coupling to thin filaments with HCM and DCM mutations

Our observation that EGCG reduces Ca^{2+}-sensitivity 2-3 fold both in human thin filaments and in mouse myofibrils with only small effects on maximum sliding speed, isometric force or Hill coefficient, is in accord with previous measurements in skinned cardiac muscle fibres 21, 23. Moreover we have demonstrated that the phosphorylation-dependent shift in myofilament Ca^{2+}-sensitivity is unaffected by EGCG in both isolated filaments and intact myofibrils, in contrast to the Ca^{2+}-sensitisers (Figures 2, 3 and 6).

EGCG was also able to decrease the Ca^{2+}-sensitivity of phosphorylated thin filaments containing HCM and DCM-causing mutations, however it had different effects on phosphorylated and unphosphorylated thin filaments. With phosphorylated troponin, EGCG decreased Ca^{2+}-sensitivity similarly to wild-type troponin, but EGCG either had no effect or increased Ca^{2+}-sensitivity with unphosphorylated troponin (Table 2). This resulted in the restoration of the coupling of Ca^{2+}-sensitivity change to TnI phosphorylation (Figures 3, 4 and 5).

The ability of EGCG to re-couple all the uncoupled mutations in any of the thin filament proteins equally (actin, tropomyosin, TnI, TnT and TnC; Figures 4 and 5 9, 17) is compatible with a common mechanism for uncoupling and implies that the primary effect of EGCG would be to re-stabilize the unphosphorylated state of the TnI 1-30 peptide. We have previously demonstrated that uncoupling and absolute Ca^{2+}-sensitivity are not related when comparing a series of DCM-causing mutations 9 so the Ca^{2+}-desensitising and re-coupling

activities of EGCG may involve separate activities. Indeed, we have found analogues of EGCG that do not affect Ca^{2+}-sensitivity but can still re-couple.

Several studies have located EGCG binding in the C-terminal domain of TnC in the region of the hydrophobic cleft 21, 22, 46. Molecular Dynamics (MD) simulation suggests that it can bind in several interchangeable orientations 46 and unlike EMD57033, EGCG can bind to the C-terminal domain of cTnC even in the presence of TnI 34-71 helix 46. We suggest that it is possible that EGCG can restabilise the TnI – TnC interaction, restoring the Ca^{2+} response to phosphorylation found in DCM and HCM. MD calculations indicate that the uncoupling mutation cTnC G159D strengthens TnI 34-71 helix binding to the hydrophobic cleft whilst EGCG weakens this interaction 46, compatible with their opposite effects on coupling.

Effects of EGCG on myofibrillar contractility

EGCG decreased Ca^{2+}-sensitivity in phosphorylated and unphosphorylated wild-type myofibrils by ~2 fold but did not change the relaxation parameters t_{LIN} and k_{REL} in phosphorylated myofibrils (see Table 3). The rate of force development (k_{ACT}), measured at high Ca^{2+}, was unchanged in myofibrils with phosphorylated TnI and slightly decreased (p=0.059) in unphosphorylated myofibrils. As k_{ACT} depends strongly on the Ca^{2+} concentration 10, we conclude that EGCG shifts the $[Ca^{2+}]$-k_{ACT} relationship towards higher Ca^{2+} concentration in agreement with IVMA data (Table 1). Thus, unlike EMD57033, EGCG decreases cross-bridge activation kinetics 10.

EGCG reduced Ca^{2+}-sensitivity and k_{ACT} in both phosphorylated and unphosphorylated *ACTC* E361G myofibrils. In addition it restored the lost difference in Ca^{2+}-sensitivity between phosphorylated and unphosphorylated myofibrils and also the difference in the relaxation parameter t_{LIN} (Table 3). The observation that EGCG does not affect the EC_{50} P/EC_{50} unP or t_{LIN} in wild-type myofibrils but changes them in *ACTC* E361G, suggests that EGCG can restore coupling in *ACTC* E361G myofibrils independently of its Ca^{2+}-desensitising function.

Although uncoupling can be clearly demonstrated at the level of skinned muscle fibres or myocytes with thin filament mutations causing DCM 35, 48, 49 this does not appear to be true for HCM-causing mutations, despite being indistinguishable at the single filament level. A near-normal response of Ca^{2+}-sensitivity to TnI phosphorylation has been reported for *TNNC1* L29Q and *TPM1* E180G in transgenic mice 50, 51 and *TNNI3* R145W and *TNNT2* K280N in human heart myectomy samples 16. Despite this, both DCM and HCM linked mutations in transgenic mice models are associated with an impaired response to β1-adrenergic stimulation and reduced cardiac reserve as would be expected if uncoupled 15, 35 (reviewed by Messer 17). The physiological manifestations of the uncoupling seen in unloaded filaments requires further investigation.

Clinical relevance of re-coupling by EGCG

Ca^{2+}-antagonists have been suggested as being potentially useful for treatment of HCM 52. EGCG represents a new class of Ca^{2+}-antagonists with a very favourable functional profile. EGCG acts directly on the Ca^{2+}-regulatory system of the thin filament that is also the main

target of HCM-causing mutations in sarcomeric proteins 5. By binding to troponin it decreases the enhanced Ca^{2+}-sensitivity characteristic of HCM whilst also reversing the uncoupling effect we observed in HCM mutations. The ability to restore coupling to DCM mutant myofibrils could be beneficial, since this was proposed to be the primary cause of DCM, but the reduction in Ca^{2+}-sensitivity in cases where the mutation reduces Ca^{2+}-sensitivity may be deleterious.

EGCG has a wide range of pharmacological properties; indeed it has been cited as an example of a promiscuous molecule 53. Moreover, low doses of EGCG have a positive inotropic effect in intact heart muscle, due to effects on the ryanodine receptor type 2, Na^+-K^+ ATPase and Na^+-Ca^{2+} Exchanger, that may override the Ca^{2+}-desensitising effect in the contractile apparatus 54, 55.

Although EGCG is too non-specific to be a viable drug for treating HCM, this study has demonstrated a significant proof of principle: it is possible to directly reverse the molecular mechanism of HCM-causing mutations pharmacologically. The coupling of Ca^{2+}-sensitivity to cTnI phosphorylation has been demonstrated to be a labile property of troponin. HCM or DCM mutations and Ca^{2+}-sensitisers can induce uncoupling, indicating that small perturbations can destabilise troponin 9, 17, 32. It is very unusual to find a reagent that will give a gain of function by apparently restoring the native conformational state in the presence of mutations that destabilised this state.

Our findings provide a starting point for investigating molecules related to EGCG that may be more efficacious and act specifically on troponin 56.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements

Abbreviations

DCM	Dilated Cardiomyopathy
EGCG	Epigallocatechin-3-Gallate
F_{MAX}	Maximum force
HCM	Hypertrophic Cardiomyopathy

IVMA	*In vitro* Motility Assay
k_{ACT}	Rate of force development
k_{REL}	Rate of fast relaxation phase
MD	Molecular Dynamics
n_H	Hill Coefficient
P	Phosphorylated
PKA	Protein Kinase A
t_{LIN}	Duration of slow relaxation phase
TnC	Troponin C
TnI	Troponin I
TnT	Troponin T
unP	Unphosphorylated

References

1. Elliott P, McKenna WJ. Hypertrophic cardiomyopathy. Lancet. 2004; 363:1881–1891. [PubMed: 15183628]

2. Seidman JG, Seidman C. The genetic basis for cardiomyopathy: From mutation identification to mechanistic paradigms. Cell. 2001; 104:557–567. [PubMed: 11239412]

3. Hershberger RE, Hedges DJ, Morales A. Dilated cardiomyopathy: The complexity of a diverse genetic architecture. Nat Rev Cardiol. 2013; 10:531–547. [PubMed: 23900355]

4. Kamisago M, Sharma SD, DePalma SR, Solomon S, Sharma P, Smoot L, Mullen MP, Woolf PK, Wigle ED, Seidman JG, Seidman CE, et al. Mutations in sarcomere protein genes as a cause of dilated cardiomyopathy. N Engl J Med. 2000; 343:1688–1696. [PubMed: 11106718]

5. Marston SB. How do mutations in contractile proteins cause the primary familial cardiomyopathies? J Cardiovasc Transl Res. 2011; 4:245–255. [PubMed: 21424860]

6. Morimoto S. Sarcomeric proteins and inherited cardiomyopathies. Cardiovasc Res. 2008; 77:659–666. [PubMed: 18056765]

7. Knollmann BC, Potter JD. Altered regulation of cardiac muscle contraction by troponin t mutations that cause familial hypertrophic cardiomyopathy. Trends Cardiovasc Med. 2001; 11:206–212. [PubMed: 11597833]

8. Chang AN, Potter JD. Sarcomeric protein mutations in dilated cardiomyopathy. Heart Fail Rev. 2005; 10:225–235. [PubMed: 16416045]

9. Memo M, Leung M-C, Ward DG, dos Remedios C, Morimoto S, Zhang L, Ravenscroft G, McNamara E, Nowak KJ, Marston SB, Messer AE. Mutations in thin filament proteins that cause familial dilated cardiomyopathy uncouple troponin i phosphorylation from changes in myofibrillar ca2+-sensitivity. Cardiovasc Res. 2013; 99:65–73. [PubMed: 23539503]

10. Vikhorev PG, Song W, Wilkinson R, Copeland O, Messer AE, Ferenczi MA, Marston SB. The dilated cardiomyopathy-causing mutation actc e361g in cardiac muscle myofibrils specifically abolishes modulation of ca2+ regulation by phosphorylation of troponin i. Biophys J. 2014; 107:2369–2380. [PubMed: 25418306]

11. Schmidtmann A, Lindow C, Villard S, Heuser A, Mügge A, Gessner R, Granier C, Jaquet K. Cardiac troponin c-l29q, related to hypertrophic cardiomyopathy, hinders the transduction of the

protein kinase a dependent phosphorylation signal from cardiac troponin i to c. FEBS J. 2005; 272:6087–6097. [PubMed: 16302972]

12. Dong W, Xing J, Ouyang Y, An J, Cheung HC. Structural kinetics of cardiac troponin c mutants linked to familial hypertrophic and dilated cardiomyopathy in troponin complexes. J Biol Chem. 2008; 283:3424–3432. [PubMed: 18063575]

13. Deng Y, Schmidtmann A, Redlich A, Westerdorf B, Jaquet K, Thieleczek R. Effects of phosphorylation and mutation r145g on human cardiac troponin i function. Biochemistry. 2001; 40:14593–14602. [PubMed: 11724573]

14. Wang Y, Pinto J, Sancho Solis R, Dweck D, Liang J, Diaz-Perez Z, Ge Y, Walker J, Potter J. The generation and functional characterization of knock in mice harboring the cardiac troponin i-r21c mutation associated with hypertrophic cardiomyopathy. J Biol Chem. 2011; 287:2156–2167. [PubMed: 22086914]

15. Song W, Dyer E, Stuckey D, Copeland O, Leung M, Bayliss C, Messer AE, Wilkinson R, Tremoleda J, Schneider M, Harding S, et al. Molecular mechanism of the glu99lys mutation in cardiac actin (actc gene) that causes apical hypertrophy in man and mouse. J Biol Chem. 2011; 286:27582–27593. [PubMed: 21622575]

16. Sequeira V, Wijnker PJM, Nijenkamp LLAM, Kuster DWD, Najafi A, Witjas-Paalberends ER, Regan JA, Boontje N, ten Cate FJ, Germans T, Carrier L, et al. Perturbed length-dependent activation in human hypertrophic cardiomyopathy with missense sarcomeric gene mutations. Circ Res. 2013; 112:1491–1505. [PubMed: 23508784]

17. Messer A, Marston S. Investigating the role of uncoupling of troponin i phosphorylation from changes in myofibrillar ca2+-sensitivity in the pathogenesis of cardiomyopathy. Front Physiol. 2014; 5:315. [PubMed: 25202278]

18. Li MX, Robertson IM, Sykes BD. Interaction of cardiac troponin with cardiotonic drugs: A structural perspective. Biochem Biophys Res Commun. 2008; 369:88–99. [PubMed: 18162171]

19. Wang X, Li MX, Spyracopoulos L, Beier N, Chandra M, Solaro RJ, Sykes BD. Structure of the c-domain of human cardiac troponin c in complex with the ca2+ sensitizing drug emd 57033. J Biol Chem. 2001; 276:25456–25466. [PubMed: 11320096]

20. Abusamhadneh E, Abbott MB, Dvoretsky A, Finley N, Sasi S, Rosevear PR. Interaction of bepridil with the cardiac troponin c/troponin i complex. FEBS Lett. 2001; 506:51–54. [PubMed: 11591369]

21. Liou Y-M, Kuo S-C, Hsieh S-R. Differential effects of a green tea-derived polyphenol (-)-epigallocatechin-3-gallate on the acidosis-induced decrease in the ca(2+) sensitivity of cardiac and skeletal muscle. Pflugers Arch. 2008; 456:787–800. [PubMed: 18231806]

22. Robertson IM, Li MX, Sykes BD. Solution structure of human cardiac troponin c in complex with the green tea polyphenol, (-)-epigallocatechin 3-gallate. J Biol Chem. 2009; 284:23012–23023. [PubMed: 19542563]

23. Tadano N, Du C, Yumoto F, Morimoto S, Ohta M, Xie M, Nagata K, Zhan D, Lu Q, Miwa Y, Takahashi-Yanaga F, et al. Biological actions of green tea catechins on cardiac troponin c. Brit J Pharmacol. 2010; 161:1034–1043. [PubMed: 20977454]

24. Takeda N, Yamashita A, Maeda K, Maeda Y. Structure of the core domain of human cardiac troponin in the ca2+-saturated form. Nature. 2003; 424:35–41. [PubMed: 12840750]

25. Solaro RJ, Rosevear P, Kobayashi T. The unique functions of cardiac troponin i in the control of cardiac muscle contraction and relaxation. Biochem Biophys Res Commun. 2008; 369:82–87. [PubMed: 18162178]

26. Howarth JW, Meller J, Solaro RJ, Trewhella J, Rosevear PR. Phosphorylation-dependent conformational transition of the cardiac specific n-extension of troponin i in cardiac troponin. J Mol Biol. 2007; 373:706–722. [PubMed: 17854829]

27. Gould I, Messer AE, Papadaki M, Marston SB. *modulation of the interaction between troponin i n-terminal peptide and troponin c by phosphorylation studied by molecular dynamics. Biophys J. 2014; 106:349a.

28. Cheng Y, Lindert S, Kekenes-Huskey P, Rao VS, Solaro RJ, Rosevear PR, Amaro R, McCulloch AD, McCammon JA, Regnier M. Computational studies of the effect of the s23d/s24d troponin i

mutation on cardiac troponin structural dynamics. Biophys J. 2014; 107:1675–1685. [PubMed: 25296321]

29. Messer AE, Jacques AM, Marston SB. Troponin phosphorylation and regulatory function in human heart muscle: Dephosphorylation of ser23/24 on troponin i could account for the contractile defect in end-stage heart failure. J Mol Cell Cardiol. 2007; 42:247–259. [PubMed: 17081561]

30. Dyer E, Jacques A, Hoskins A, Ward D, Gallon C, Messer A, Kaski J, Burch M, Kentish J, Marston S. Functional analysis of a unique troponin c mutation, gly159asp that causes familial dilated cardiomyopathy, studied in explanted heart muscle. Circ Heart Fail. 2009; 2:456–464. [PubMed: 19808376]

31. Carballo S, Robinson P, Otway R, Fatkin D, Jongbloed JD, de Jonge N, Blair E, van Tintelen JP, Redwood C, Watkins H. Identification and functional characterization of cardiac troponin i as a novel disease gene in autosomal dominant dilated cardiomyopathy. Circ Res. 2009; 105:375–382. [PubMed: 19590045]

32. Bayliss CR, Jacques AM, Leung M-C, Ward DG, Redwood CS, Gallon CE, Copeland O, Mckenna WJ, Dos Remedios C, Marston SB, Messer AE. Myofibrillar ca2+-sensitivity is uncoupled from troponin i phosphorylation in hypertrophic obstructive cardiomyopathy due to abnormal troponin t. Cardiovasc Res. 2012; 97:500–508. [PubMed: 23097574]

33. Akkari PA, Song Y, Hitchcock-DeGregori S, Blechynden L, Laing N. Expression and biological activity of baculovirus generated wild-type human slow alpha tropomyosin and the met9arg mutant responsible for a dominant form of nemaline myopathy. Biochem Biophys Res Commun. 2002; 296:300–304. [PubMed: 12163017]

34. Marston S, Memo M, Messer A, Papadaki M, Nowak K, McNamara E, Ong R, El-Mezgueldi M, Li X, Lehman W. Mutations in repeating structural motifs of tropomyosin cause gain of function in skeletal muscle myopathy patients. Hum Mol Genet. 2013; 22:4978–4987. [PubMed: 23886664]

35. Song W, Dyer E, Stuckey D, Leung M-C, Memo M, Mansfield C, Ferenczi M, Liu K, Redwood C, Nowak K, Harding S, et al. Investigation of a transgenic mouse model of familial dilated cardiomyopathy. J Mol Cell Cardiol. 2010; 49:380–389. [PubMed: 20600154]

36. Messer A, Gallon C, McKenna W, Elliott P, Dos Remedios C, Marston S. The use of phosphate-affinity sds-page to measure the troponin i phosphorylation site distribution in human heart muscle. Proteomics Clin Appl. 2009; 3:1371–1382. [PubMed: 21136957]

37. Fraser IDC, Marston SB. *In vitro* motility analysis of actin-tropomyosin regulation by troponin and ca2+: The thin filament is switched as a single cooperative unit. J Biol Chem. 1995; 270:7836–7841. [PubMed: 7713874]

38. Marston SB, Fraser IDC, Wu B, Roper G. A simple method for automatic tracking of actin filaments in the motility assay. J Musc Res Cell Motil. 1996; 17:497–506.

39. Bayliss C, Messer A, Leung M-C, Ward D, van der Velden J, Poggesi C, Redwood C, Marston S. *functional investigation of troponin with the homozygous hcm mutation, tnnt2 k280m, obtained from an explanted heart. Cardiovasc Res. 2012; 93:S107.

40. Baudenbacher F, Schober T, Pinto JR, Sidorov VY, Hilliard F, Solaro RJ, Potter JD, Knollmann BC. Myofilament ca2+ sensitization causes susceptibility to cardiac arrhythmia in mice. J Clin Invest. 2008; 118:3893–3903. [PubMed: 19033660]

41. Solaro RJ, Gambassi G, Warshaw DM, Keller MR, Spurgeon HA, Beier N, Lakatta EG. Stereoselective actions of thiadiazinones on canine cardiac myocytes and myofilaments. Circ Res. 1993; 73:981–990. [PubMed: 8222092]

42. Wolska BM, Kitada Y, Palmiter KA, Westfall MV, Johnson MD, Solaro RJ. Cgp-48506 increases contractility of ventricular myocytes and myofilaments by effects on actin-myosin reaction. Am J Physiol. 1996; 270:H24–32. [PubMed: 8769730]

43. Ward DG, Brewer SM, Calvert MJ, Gallon CE, Gao Y, Trayer IP. Characterization of the interaction between the n-terminal extension of human cardiac troponin i and troponin c. Biochemistry. 2004; 43:4020–4027. [PubMed: 15049709]

44. Baryshnikova OK, Li MX, Sykes BD. Modulation of cardiac troponin c function by the cardiac-specific n-terminus of troponin i: Influence of pka phosphorylation and involvement in cardiomyopathies. J Mol Biol. 2008; 375:735–751. [PubMed: 18042489]

45. Kleerekoper Q. Identification of binding sites for bepridil and trifluoperazine on cardiac troponin c. J Biol Chem. 1998; 273:8153–8160. [PubMed: 9525919]

46. Botten D, Fugallo G, Fraternali F, Molteni C. A computational exploration of the interactions of the green tea polyphenol (-)-epigallocatechin 3-gallate with cardiac muscle troponin c. PLoS ONE. 2013; 8:e70556. [PubMed: 23923004]

47. Manning EP, Tardiff JC, Schwartz SD. Molecular effects of familial hypertrophic cardiomyopathy-related mutations in the tnt1 domain of ctnt. J Mol Biol. 2012; 421:54–66. [PubMed: 22579624]

48. Biesiadecki BJ, Kobayashi T, Walker JS, John Solaro R, de Tombe PP. The troponin c g159d mutation blunts myofilament desensitization induced by troponin i ser23/24 phosphorylation. Circ Res. 2007; 100:1486–1493. [PubMed: 17446435]

49. Pinto JR, Siegfried JD, Parvatiyar MS, Li D, Norton N, Jones MA, Liang J, Potter JD, Hershberger RE. Functional characterization of tnnc1 rare variants identified in dilated cardiomyopathy. J Biol Chem. 2011; 286:34404–34412. [PubMed: 21832052]

50. Alves ML, Dias FAL, Gaffin RD, Simon JN, Montminy EM, Biesiadecki BJ, Hinken AC, Warren CM, Utter MS, Davis RT, Sakthivel S, et al. Desensitization of myofilaments to ca2+ as a therapeutic target for hypertrophic cardiomyopathy with mutations in thin filament proteins. Circ: Cardiovasc Genet. 2014; 7:132–143. [PubMed: 24585742]

51. Li AY, Stevens CM, Liang B, Rayani K, Little S, Davis J, Tibbits GF. Familial hypertrophic cardiomyopathy related cardiac troponin c l29q mutation alters length-dependent activation and functional effects of phosphomimetic troponin i*. PLoS ONE. 2013; 8:e79363. [PubMed: 24260207]

52. Semsarian C, Ahmad I, Giewat M, Georgakopoulos D, Schmitt JP, McConnell BK, Reiken S, Mende U, Marks AR, Kass DA, Seidman CE, et al. The l-type calcium channel inhibitor diltiazem prevents cardiomyopathy in a mouse model. J Clin Invest. 2002; 109:1013–1020. [PubMed: 11956238]

53. Ingólfsson HI, Thakur P, Herold KF, Hobart EA, Ramsey NB, Periole X, de Jong DH, Zwama M, Yilmaz D, Hall K, Maretzky T, et al. Phytochemicals perturb membranes and promiscuously alter protein function. ACS chemical biology. 2014; 9:1788–1798. [PubMed: 24901212]

54. Hotta Y, Huang L, Muto T, Yajima M, Miyazeki K, Ishikawa N, Fukuzawa Y, Wakida Y, Tushima H, Ando H, Nonogaki T. Positive inotropic effect of purified green tea catechin derivative in guinea pig hearts: The measurements of cellular ca2+ and nitric oxide release. Eur J Pharmacol. 2006; 552:123–130. [PubMed: 17059816]

55. Feng W, Hwang HS, Kryshtal DO, Yang T, Padilla IT, Tiwary AK, Puschner B, Pessah IN, Knollmann BC. Coordinated regulation of murine cardiomyocyte contractility by nanomolar (-)-epigallocatechin-3-gallate, the major green tea catechin. Mol Pharmacol. 2012; 82:993–1000. [PubMed: 22918967]

56. Khandelwal A, Hall JA, Blagg BSJ. Synthesis and structure–activity relationships of egcg analogues, a recently identified hsp90 inhibitor. J Org Chem. 2013; 78:7859–7884. [PubMed: 23834230]

A **native**

B *TPM1* E180G

Figure 1. Relationship between EC$_{50}$ and TnI phosphorylation in native human thin filaments and thin filaments containing HCM-causing mutation *TPM1* E180G.

Sliding speed and fraction of filaments motile, measured in the same experiment by *in vitro* motility assay (IVMA) is plotted against [Ca^{2+}] for representative experiments. Raw data from one experiment is shown here, the mean values of EC$_{50}$ from replicate experiments is shown in Table 2. Solid lines and points, phosphorylated troponin (P); dotted lines and open points, unphosphorylated troponin (unP). Error bars represent SEM of 4 measurements of motility in the same motility chamber. Blue, native thin filaments; purple, HCM-causing mutation *TPM1* E180G present.

A. Native thin filaments: phosphorylation increased EC$_{50}$ (decreased Ca^{2+}-sensitivity) but had no effect on the maximum sliding speed or fraction of filaments motile at saturating Ca^{2+}.

B. Thin filaments containing *TPM1* E180G HCM-causing mutation. The relationship of Ca^{2+}-sensitivity to TnI phosphorylation is uncoupled.

Figure 2. Effect of Ca^{2+}-sensitisers on Ca^{2+} control of motility.

A, B, D, E. Fraction of filaments motile, measured by IVMA is plotted against $[Ca^{2+}]$ for representative experiments, details as for Figure 1.

A, D. Effect of Ca^{2+}-sensitisers on Ca^{2+}-regulation of native thin filaments. Blue, native thin filaments; orange, presence of 30 μM EMD57033; brown, presence of 100 μM Bepridil.

B, E. Effect of Ca^{2+}-sensitisers on Ca^{2+}-regulation of thin filaments containing the *TPM1* E54K DCM-causing mutation. Red, E54K-containing thin filaments; orange, presence of 30 μM EMD57033; brown, presence of 100 μM Bepridil.

C. EMD57033 dose response curve: EC_{50} was determined at a range of EMD57033 concentrations. The change in EC_{50} (± SEM of 4 measurements of motility in the same motility chamber) is plotted for three separate experiments.

F. Bepridil dose response curve: motility was measured at a constant 0.037 μM Ca^{2+} with increasing concentrations of Bepridil. The increase in fraction of filaments motile (± SEM of 4 measurements of motility in the same motility chamber) is plotted for three separate experiments and the curve represents the fit of the pooled data to the Hill equation. Values of parameters obtained are shown.

Figure 3. Effect of EGCG on Ca^{2+} control of motility.
A, B. Fraction of filaments motile, measured by IVMA, is plotted against $[Ca^{2+}]$ for representative experiments, details as for Figure 1. Raw data from one experiment is shown here, the mean values of EC_{50} from replicate experiments are shown in Tables 1 and 2.
A. Effect of EGCG on Ca^{2+}-regulation of native thin filaments. Blue, native thin filaments; green, presence of 100 μM EGCG.
B. Effect of EGCG on Ca^{2+}-regulation of thin filaments containing *TPM1* E54K DCM-causing mutation. Red, E54K-containing thin filaments; green, presence of 100 μM EGCG.
C, D. Dose response curves, the fraction motile was measured at a constant $[Ca^{2+}]$ with increasing concentrations of EGCG for a representative experiment.

C. Effect of EGCG on donor thin filaments at 0.074 µM Ca^{2+}. The inset plots the change in fraction motility with increasing EGCG concentration and the curve represents the fit of the pooled data to the Hill equation. Values of parameters obtained are shown.

D. Effect of EGCG on thin filaments containing *TPM1* E180G tropomyosin at 0.037 µM Ca^{2+}. Initially, motility is the same (see Figure 1); the addition of EGCG reduced motility of phosphorylated and increased motility of unphosphorylated thin filaments, indicating recoupling or the restoration of the phosphorylation-dependent Ca^{2+}-sensitivity difference (see Figure 3B). Details as for Figure 2F.

Figure 4. Coupling is restored to HCM and DCM mutations by EGCG.
Fraction of filaments motile, measured by IVMA in the presence of 100 μM EGCG is plotted against $[Ca^{2+}]$ for representative single experiments. Details as for Figure 1. Red lines, thin filaments containing DCM-causing mutations, Purple lines, thin filaments containing HCM-causing mutations.

The mean values of EC_{50} from replicate experiments are plotted in Figure 5 and summarised in Table 2.

Figure 5. The re-coupling effect of EGCG.

The ratio EC_{50} phosphorylated/EC_{50} unphosphorylated (coupling constant) is plotted in the absence (blue) and presence (green, red and purple) of 100 μM EGCG. Green, control troponin; red, DCM-causing mutants; purple, HCM-causing mutants, error bars are ± SEM. All the mutant samples are uncoupled but the coupling constant is restored to control levels by EGCG. Data from Table 2.

A

B

Figure 6. EGCG restores the relationship between Ca^{2+}-sensitivity of force production and TnI phosphorylation in wild-type and *ACTC* E361G mouse myofibrils.

Phosphorylation level was reduced by propranolol treatment and measured by phosphate affinity SDS-PAGE. Basally phosphorylated wild-type was 1.02±0.03 and *ACTC* E361G was 1.08±0.01 mols Pi/mol TnI. For propranolol-treated (dephosphorylated) muscle the phosphorylation level was 0.30±0.04 in wild-type and 0.34±0.07 mols Pi/mol TnI for *ACTC* E361G.

A. Ca^{2+}-activation curves for *ACTC* E361G myofibrils in the presence (green) and absence (red) of 10 μM EGCG. Solid lines and points, phosphorylated troponin (P); dotted lines and open points, unphosphorylated troponin (unP). The plot shows averaged isometric tension ± SEM from 11-14 myofibrils for experiments performed at SL=2.17 μm. EGCG shifts the activation curve to the right and restores the difference between phosphorylated and unphosphorylated myofibrils.

B. Effects of the *ACTC* E361G mutation, phosphorylation and EGCG on the mean EC_{50} (± SEM) for myofibril isometric contraction. Significant differences, calculated by t-test, between phosphorylated and unphosphorylated myofibrils are indicated: ** $p < 0.01$; *** $p < 0.001$. Data from Table 3.

Table 1

Effect of EMD57033, Bepridil and EGCG on Ca^{2+}-regulation of motility

TREATMENT		EC_{50}	n_H	V_{max}	$EC_{50,}$ TPM1 E54K DCM mutation
Native	P	0.16±0.03(4)	2.08±0.14(4)	1.40±0.11(4)	0.12±0.02(3)
	unP	0.091±0.014(4)[†]	1.51±0.25(4)[†]	1.30±0.04(4)	0.11±0.008(3)
+EMD57033	P	0.057±0.010(4)[**]	1.26±0.07(4)[*]	1.55±0.08(4)	0.041±0.002(3)[*]
+EMD57033	unP	0.053±0.010(4)	1.34±0.14(4)	1.54±0.08(4)[*]	0.041±0.002(3)[*]
Native	P	0.13±0.007(8)	2.89±0.48(8)	2.09±0.14(8)	0.13±0.014(3)
	unP	0.072±0.002(6)[††]	1.96±0.08(6)	2.13±0.20(6)	0.13±0.012(3)
+Bepridil	P	0.045±0.001(8)[**]	1.94±0.08(8)	2.40±0.15(8)[**]	0.060±0.009(3)[*]
+Bepridil	unP	0.045±0.001(6)[**]	2.03±0.13(6)	2.24±0.16(6)	0.058±0.006(3)[**]
Native	P	0.14±0.03(7)	1.61±0.19(7)	1.91±0.18(7)	0.11±0.01(5)
	unP	0.059±0.011(6)[††]	1.50±0.21(6)	1.92±0.22(6)	0.11±0.02(5)
+EGCG	P	0.26±0.02(7)[**]	1.96±0.24(7)	1.38±0.12(7)[**]	0.23±0.03(5)[*]
+EGCG	unP	0.15±0.02(6)[**††]	1.79±0.30(6)	1.52±0.13(6)[*]	0.071±0.005(5)[††]

[*]
$p < 0.05$

[**]
$p < 0.01$; for presence and absence of reagent

[†]
$p < 0.05$

[††]
$p < 0.01$; unphosphorylated compared with phosphorylated. Paired t test was used for EC_{50}, n_H and V_{max} (the change in velocity due to Ca^{2+}). EC_{50} values rounded to 2 significant figures. In brackets is the number of experiments.

Table 2

Effect of EGCG and TnI phosphorylation on the Ca^{2+}-sensitivity of thin filaments containing HCM and DCM mutations.

Mutation	EC$_{50}$ of thin filaments containing phosphorylated troponin μM ± SEM	EC$_{50}$ of thin filaments containing unphosphorylated troponin μM ± SEM	Ratio EC$_{50}$ P / unP ± SEM	EC$_{50}$ of thin filaments treated with EGCG containing phosphorylated troponin μM ± SEM	EC$_{50}$ of thin filaments treated with EGCG containing unphosphorylated troponin μM ± SEM	Ratio EC$_{50}$ P + EGCG / unP + EGCG ± SEM	Ratio EC$_{50}$ P + EGCG / P ± SEM	Ratio EC$_{50}$ unP + EGCG / unP ± SEM
WT	0.14 ± 0.03(7)	0.059 ± 0.011(6) [††]	2.24 ± 0.10(6) [††]	0.26 ± 0.02(7) [**]	0.15 ± 0.02(6) [**††]	1.73 ± 0.16(6) [††]	2.15 ± 0.45(7)	2.80 ± 0.48(6)
DCM								
TPM1 E54K	0.11 ± 0.013(5)	0.11 ± 0.02(5)	0.95 ± 0.03(5)	0.23 ± 0.03(5) [*]	0.071 ± 0.005(5) [††]	3.17 ± 0.37(5) [††]	2.33 ± 0.53(5)	0.68 ± 0.10(5)
TPM1 E40K	0.18 ± 0.03(8)	0.17 ± 0.03(8)	1.02 ± 0.007(8)	0.22 ± 0.04(5)	0.052 ± 0.01(5) [*†]	4.63 ± 0.96(5) [†]	1.70 ± 0.43(3)	0.34 ± 0.05(3)
TNNC1 G159D	0.092 ± 0.004(5)	0.095 ± 0.005(5)	0.97 ± 0.03(5)	0.19 ± 0.03(5) [*]	0.088 ± 0.005(5) [*†]	2.25 ± 0.41(5) [†]	2.13 ± 0.36(5)	0.93 ± 0.02(5)
TNNI3 K36Q	0.18 ± 0.03(10)	0.18 ± 0.04(10)	1.02 ± 0.05(10)	0.19 ± 0.02(5)	0.10 ± 0.009(5) [*†]	1.97 ± 0.12(5) [†]	2.32 ± 0.29(3)	1.28 ± 0.04(3)
ACTC E361G	0.087 ± 0.002(5)	0.080 ± 0.002(5)	1.08 ± 0.02(5)	0.20 ± 0.02(5) [**]	0.081 ± 0.002(5) [††]	2.41 ± 0.28(5) [††]	2.27 ± 0.28(5)	1.01 ± 0.02(5)
HCM								
TPM1 E180G	0.086 ± 0.013(3)	0.087 ± 0.011(3)	0.98 ± 0.02(3)	0.11 ± 0.01(5) [*]	0.048 ± 0.003(5) [*†]	2.41 ± 0.32(5) [†]	1.36 ± 0.10(3)	0.51 ± 0.06(3)
TNNT2 K280N	0.11 ± 0.007(5)	0.10 ± 0.004(5)	1.08 ± 0.04(5)	0.20 ± 0.03(5) [*]	0.10 ± 0.004(5) [†]	1.96 ± 0.24(5) [†]	2.15 ± 0.18(3)	1.09 ± 0.006(3)
ACTC E99K	0.074 ± 0.005(5)	0.074 ± 0.005(5)	0.99 ± 0.02(5)	0.21 ± 0.03(5) [**]	0.10 ± 0.007(5) [**††]	2.03 ± 0.21(5) [††]	2.85 ± 0.28(5)	1.43 ± 0.13(5)

[*]
p<0.05

[**]
p<0.01; for presence and absence of EGCG

[†]
p<0.05

[††]
p<0.01; unphosphorylated compared with phosphorylated using paired t test. Ratios: single value t test compared with 1. ANOVA analysis of this dataset is shown in Supplement E. EC$_{50}$ values rounded to 2 significant figures. In brackets is the number of experiments.

Table 3

Effect of phosphorylation, *ACTC* E361G mutation and EGCG on Ca²⁺-regulation of myofibril contraction.

In brackets is the number of experiments. Statistical analysis carried out by un-paired t test (equal variance).

		F_{max}, kN/m²	EC_{50}, μM	n_H	k_{ACT}, s⁻¹	t_{LIN}, ms	k_{REL}, S⁻¹
WT‖	P	100.9±6.3(14)	0.93±0.06(11)	10.43±1.84(10)	4.16±0.43(11)	50.8±3.5(12)	35.0±4.0(10)
	unP	87.1±6.0(16)	0.51±0.06(14)†††	4.74±0.66(13)††	4.50±0.24(15)	67.0±4.2(16)†	23.2±2.8(11)†††
WT+EGCG	P	92.5±5.0(15)	1.85±0.17(9)***	4.30±0.85(8)**	4.44±0.24(15)	46.7±3.9(12)	41.0±4.0(12)
	unP	92.6±8.9(8)	1.13±0.13(5)††***	5.08±1.24(5)	3.47±0.55(6)	88.9±9.9(7)†††*	22.3±1.2(7)††
E361G‖	P	93.5±8.9(11)	0.38±0.05(12)§§§	5.39±1.26(9)§	4.51±0.32(13)	75.4±6.5(10)§§	21.6±2.8(10)§§§
	unP	89.3±8.6(10)	0.43±0.06(10)	4.48±0.708(8)	4.12±0.32(11)	70.8±9.7(11)	21.6±2.1(10)
E361G+EGCG	P	89.1±4.5(12)	2.07±0.20(5)***†††	7.18±1.54(5)	3.43±0.20(13)*§††	49.7±3.3(12)**	31.0±2.6(12)*§
	unP	96.3±11.1(11)	1.28±0.10(8)††***†††	4.14±0.42(7)†	3.25±0.26(11)***††	63.0±4.7(12)†§	31.0±2.0(12)**§§††

*
  p<0.05

**
  p<0.01

***
  p<0.001; EGCG treated compared with no EGCG.

†
  p<0.05

††
  p<0.01

†††
  p<0.001; unphosphorylated compared with phosphorylated.

§
  p<0.05

§§
  p<0.01

§§§
  p<0.001; *ACTC*E361G compared with wild-type.

‡
  p<0.05

‡‡
  p<0.01

†††p<0.001; *ACTC*E361G EGCG treated compared with no EGCG wild-type.

¶Vikhorev *et al.* 2014 11.